Clinical Treatment and Translational Advances in Myelodysplastic Syndromes and Acute Myeloid Leukemia
A Special Issue of Cancers (ISSN 2072-6694).
Deadline for manuscript submissions: 30 November 2026 | Viewed by 2260
Editors
2. UniCamillus-Saint Camillus International University of Health Sciences, Rome, Italy
Interests: de novo, secondary, and therapy-related myeloid neoplasms: individual susceptibility, risk factors, diagnostic/prognostic framework, and identification of new molecular targets and markers of treatment response
Interests: acute myeloid leukemia; myelodysplastic syndromes; myeloproliferative neoplasms; acute promyelocytic leukemia
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Myeloid neoplasms (MN), including myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML), are heterogeneous malignancies ranging from indolent chronic diseases to aggressive high-risk phenotypes. In recent years, major advances in the biological understanding of MN have significantly deepened our knowledge of the molecular drivers of disease evolution, treatment resistance, and relapse.
On the clinical side, important therapeutic breakthroughs have reshaped—and will continue to modify in the near future—the management of several MN subgroups. In lower-risk MDS, novel agents such as luspatercept, a TGF-β ligand trap, and imetelstat, a telomerase inhibitor, have demonstrated remarkable efficacy in transfusion-dependent patients. Similarly, the addition of venetoclax to intensive chemotherapy in refractory or very high-risk AML has yielded highly promising results. Targeted therapies have also expanded our armamentarium: menin inhibitors for AML with NPM1 mutations or KMT2A rearrangements, and IDH1/IDH2 inhibitors for IDH-mutated AML, are among the most notable innovations. Conversely, therapeutic progress in high-risk MDS has lagged behind. Since the introduction of hypomethylating agents (HMAs), no major breakthroughs have emerged, and recent trials combining HMAs with venetoclax, tamibarotene, sabatolimab, pevonedistat, or eprenetapopt have not demonstrated superior complete remission rates or overall survival compared to monotherapy.
This Special Issue aims to highlight recent advances across all aspects of MDS and AML management, encompassing therapeutic innovations, translational research, biomarker discovery, and novel prognostic models. We warmly welcome inquiries and encourage the submission of original research articles and comprehensive reviews aligned with the scope of this Issue.
Prof. Dr. Emiliano Fabiani
Dr. Luca Guarnera
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-anonymized peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- myeloid neoplasms
- myelodysplastic neoplasms
- acute myeloid leukemia
- leukemogenesis
- target therapy
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
